MNMD David W Gryska buys $21K worth of shares
Aug 26, 2024, 11:34 PM
0.17%
What does MNMD do
Mind Medicine (MindMed), Inc., a clinical-stage biopharmaceutical company based in New York City, focuses on developing novel treatments for brain health disorders, including products like MM-120 for GAD and ADHD, and MM-402 for ASD. The company, which went public in 2015, works on therapies targeting neurotransmitter pathways using derivatives from psychedelic and empathogen drug classes.
David W Gryska bought 3,500 shares of MNMD on 23 August at $5.98 per share, worth a total of $21K. They now own 17,351 MNMD shares, or a 25% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.